SEC Comment Letter for Stereotaxis, Inc. (STXS) (CIK 0001289340) (STXS) — Mar 19, 2020

Stereotaxis, Inc. (STXS) (CIK 0001289340)
Date: March 19, 2020 · CIK: 0001289340 · Accession: 0000000000-20-002447

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-237194

Date

March 19, 2020

Author

David Fischel

Form

UPLOAD

Company

Stereotaxis, Inc. (STXS) (CIK 0001289340)

Letter

March 19, 2020 David Fischel Chief Executive Officer Stereotaxis, Inc. 4320 Forest Park Avenue, Suite 100 St. Louis, MO 63108 Re:Stereotaxis, Inc. Registration Statement on Form S-3 Filed March 16, 2020 File No. 333-237194 Dear Mr. Fischel: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Endicott, Esq.

Show Raw Text

March 19, 2020
David Fischel
Chief Executive Officer
Stereotaxis, Inc.
4320 Forest Park Avenue, Suite 100
St. Louis, MO 63108
Re:Stereotaxis, Inc.
Registration Statement on Form S-3
Filed March 16, 2020
File No. 333-237194
Dear Mr. Fischel:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Robert Endicott, Esq.

SecProbe.io